tiprankstipranks
Advertisement
Advertisement
Immatics Calls 2026 Annual General Meeting, Sets Record Date and Details New Incentive Plan
PremiumCompany AnnouncementsImmatics Calls 2026 Annual General Meeting, Sets Record Date and Details New Incentive Plan
3M ago
Immatics Showcases Strong Phase 1 Data for PRAME and MAGEA4/8 TCR Programs at ASCO 2026
Premium
Company Announcements
Immatics Showcases Strong Phase 1 Data for PRAME and MAGEA4/8 TCR Programs at ASCO 2026
3M ago
Immatics announces presentation of extended data from Phase 1 trial of IMA401
Premium
The Fly
Immatics announces presentation of extended data from Phase 1 trial of IMA401
3M ago
Immatics Secures Four High-Profile Oral Slots for PRAME and Bispecific Programs at 2026 ASCO
PremiumCompany AnnouncementsImmatics Secures Four High-Profile Oral Slots for PRAME and Bispecific Programs at 2026 ASCO
4M ago
Immatics Highlights PRAME-Targeted Cell Therapy Remission in Pediatric Kidney Cancer, Plans Pediatric Trial Expansion
Premium
Company Announcements
Immatics Highlights PRAME-Targeted Cell Therapy Remission in Pediatric Kidney Cancer, Plans Pediatric Trial Expansion
4M ago
Immatics abstract accepted for late-breaking poster presentation at AACR meeting
Premium
The Fly
Immatics abstract accepted for late-breaking poster presentation at AACR meeting
4M ago
Immatics price target raised to $25 from $23 at Mizuho
PremiumThe FlyImmatics price target raised to $25 from $23 at Mizuho
6M ago
Immatics’ treatment of Stage II and higher CM granted FDA orphan designation
Premium
The Fly
Immatics’ treatment of Stage II and higher CM granted FDA orphan designation
6M ago
Immatics Publishes Updated PRAME-Focused Investor Presentation on January 12, 2026
Premium
Company Announcements
Immatics Publishes Updated PRAME-Focused Investor Presentation on January 12, 2026
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100